Investor Update

Basel, 10 March 2011

Herceptin® approved in Japan for additional indication of advanced or recurrent gastric cancer overexpressing HER2, which is not amenable to curative resection

Dear Investor,

Please find attached a press release by Chugai.

Do not hesitate to contact us for any further questions.